ArticlePloS one2014
Erythrocyte-derived microparticles supporting activated protein C-mediated regulation of blood coagulation.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 87 citations in OpenAlex.
- Circulating Erythrocyte- and Endothelial-Derived Microvesicles as Biomarkers of Hemolysis and Clinical Severity in Sickle Cell Disease.Journal of cellular and molecular medicine · 2025Article
- Red cell microparticles produced using high-pressure extrusion enhance both primary and secondary hemostasis.Pharmacological reports : PR · 2025Article
- Coagulation protease-induced extracellular vesicles: their potential effects on coagulation and inflammation.Journal of thrombosis and haemostasis : JTH · 2024Review
- Natural Anticoagulant Protein Levels in Patients With Beta-Thalassemia Major: A Case-Control Study.Journal of hematology · 2024Article
- Review
- Different-sized extracellular vesicles derived from stored red blood cells package diverse cargoes and cause distinct cellular effects.Transfusion · 2023Article
- Extracellular Vesicles as New Players in Drug Delivery: A Focus on Red Blood Cells-Derived EVs.Pharmaceutics · 2023Review
- TheHeliyon · 2023Article
- Article
- Blood Cell-Derived Microvesicles in Hematological Diseases and beyond.Biomolecules · 2022Review
- The regulatory role of exosomes in venous thromboembolism.Frontiers in cell and developmental biology · 2022Review
- Extracellular Vesicles Linking Inflammation, Cancer and Thrombotic Risks.Frontiers in cell and developmental biology · 2022Review
- Epithelial-Cell-Derived Extracellular Vesicles in Pathophysiology of Epithelial Injury and Repair in Chronic Rhinosinusitis: Connecting Immunology in Research Lab to Biomarkers in Clinics.International journal of molecular sciences · 2021Review
- Extracellular Vesicles and Thrombosis: Update on the Clinical and Experimental Evidence.International journal of molecular sciences · 2021Review
- Production of erythrocyte microparticles in a sub-hemolytic environment.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2021Article
- Extracellular Vesicles in Sickle Cell Disease: Plasma Concentration, Blood Cell Types Origin Distribution and Biological Properties.Frontiers in medicine · 2021Review
- Extracellular vesicles: Potential impact on cardiovascular diseases.Advances in clinical chemistry · 2021Review
- Extracellular Vesicles from Red Blood Cells and Their Evolving Roles in Health, Coagulopathy and Therapy.International journal of molecular sciences · 2020Review
- Review
- Preclinical Evaluation of Safety and Biodistribution of Red Cell Microparticles: A Novel Hemostatic Agent.Journal of cardiovascular pharmacology and therapeutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated levels of erythrocyte-derived microparticles are present in the circulation in medical conditions affecting the red blood cells. Erythrocyte-derived microparticles expose phosphatidylserine thus providing a suitable surface for procoagulant reactions leading to thrombin formation via the tenase and prothrombinase complexes. Patients with elevated levels of circulating erythrocyte-derived microparticles have increased thrombin generation in vivo. The aim of the present study was to investigate whether erythrocyte-derived microparticles are able to support the anticoagulant reactions of the protein C system. Erythrocyte-derived microparticles were isolated using ultracentrifugation after incubation of freshly prepared erythrocytes with the ionophore A23187 or from outdated erythrocyte concentrates, the different microparticles preparations yielding similar results. According to flow cytometry analysis, the microparticles exposed phoshatidylserine and bound lactadherin, annexin V, and protein S, which is a cofactor to activated protein C. The microparticles were able to assemble the tenase and prothrombinase complexes and to stimulate the formation of thrombin in plasma-based thrombin generation assay both in presence and absence of added tissue factor. The addition of activated protein C in the thrombin generation assay inhibited thrombin generation in a dose-dependent fashion. The anticoagulant effect of activated protein C in the thrombin generation assay was inhibited by a monoclonal antibody that prevents binding of protein S to microparticles and also attenuated by anti-TFPI antibodies. In the presence of erythrocyte-derived microparticles, activated protein C inhibited tenase and prothrombinase by degrading the cofactors FVIIIa and FVa, respectively. Protein S stimulated the Arg306-cleavage in FVa, whereas efficient inhibition of FVIIIa depended on the synergistic cofactor activity of protein S and FV. In summary, the erythrocyte-derived microparticle surface is suitable for the anticoagulant reactions of the protein C system, which may be important to balance the initiation and propagation of coagulation in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.